HALO News and Press, Halozyme Therapeutics Inc. From 07/23/19

SAN DIEGO , July 23, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will webcast its Quarterly Update Conference Call for the second quarter 2019 on Tuesday, August 6 at 4:30 p.m. ET ...

Johnson & Johnson (NYSE: JNJ ) unit Janssen-Cilag International NV has submitted an extension application to the European Medicines Agency (EMA) seeking approval for a subcutaneously administered formulation of multiple myeloma med DARZALEX (daratumumab). More news on: Johnson & ...

SAN DIEGO , July 19, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced that Janssen-Cilag International NV (Janssen) has submitted an extension application to the European Medicin...

SAN DIEGO , July 17, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced that argenx has dosed the first subject in a phase 1 clinical trial evaluating the safety, pharmacokine...

Genmab A/S ( OTCPK:GNMSF ) announces that licensee Janssen Biotech, a unit of Johnson & Johnson ( JNJ -5.2% ), has filed a marketing application with the FDA seeking approval for a subcutaneously administered formulation of multiple myeloma med Darzalex (daratumumab). More news on:...

SAN DIEGO , July 12, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced that its collaborator Janssen Biotech, Inc. (Janssen) has submitted a Biologics License Application (BLA) to...

Entities controlled by Randal J. Kirk sold 1,567,633 shares  of Halo Therapeutics (NASDAQ: HALO ) in  open market transactions between June 10 and July 2, 2019 for aggregate net proceeds of $26.1M, according to an SEC filing. More news on: Halozyme Therapeutics, Inc., Healt...

Halozyme ( HALO +1.4% ) enters into an agreement with the NIH's National Institute of Allergy and Infectious Diseases' Vaccine Research Center aimed at leveraging HALO's ENHANZE drug delivery technology to develop subcutaneous formulations of broadly neutralizing antibodies against HIV. ...

SAN DIEGO , June 25, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced a Cooperative Research and Development Agreement (CRADA) with the National Institute of Allergy and Infectious Diseases' Vaccine Research Center (VRC), part of the National Insti...

At its R&D Day today, argenx ( ARGX +0.5% ) will present data on two new pipeline candidates: ARGX-117, a next-generation complement-targeting antibody against C2 and ARGX-118, an antibody targeting a protein called Galectin-10 that plays a key role in severe asthma, in-licensed from B...